Frailty is highly prevalent among patients with vasculitis and is associated with adverse health outcomes and reduced HRQOL.

MANCHESTER, England — A soon-to-be-released guidance from the British Society for Rheumatology on the management of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV ...

Prophylactic trimethoprim-sulfamethoxazole lowered serious infection risk in patients with ANCA-associated vasculitis, particularly in the first 180 days after induction therapy.

ANCA Vasculitis Market Outlook 2025-2035: The ANCA-Vasculitis market reached a value of USD 339 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 537 Million by 2035, ...

Age at diagnosis of ANCA-associated vasculitis (AAV) is associated with clinical characteristics of the disease, recent study findings suggest.

Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02) ...

New findings suggest a potential link between COVID-19 mRNA vaccinations and ANCA-associated vasculitis.

Despite a stable incidence of ANCA-associated vasculitis, its prevalence has increased, indicating improved management and survival.

The FDA has approved avacopan as an adjunctive treatment for adults with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis ...

The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (eg, ANCA vasculitis) are a heterogeneous group of rare, life-threatening, immune-mediated disorders that are characterized ...

Medication keeps more patients with ANCA-associated vasculitis in remission than steroids Date: February 17, 2021 Source: University of Pennsylvania School of Medicine Summary: Avacopan, which ...